NeoVax (Dana-Farber Cancer Institute)

**NeoVax** is an investigational, patient-specific therapeutic cancer vaccine developed at Dana-Farber Cancer Institute for generating T-cell immunity against tumor neoantigens. For high-risk, fully resected clear cell renal cell carcinoma, tumor and matched normal tissue are sequenced and computationally analyzed to select up to 20 patient-specific mutant peptide neoantigens; the peptide pools are mixed with the double-stranded RNA immune adjuvant poly-ICLC and administered by subcutaneous and intradermal injection. The peptides are intended to prime and expand neoantigen-specific CD4-positive and CD8-positive T-cell responses, while poly-ICLC promotes innate immune activation. In the Phase I renal cell carcinoma study NCT02950766, NeoVax was evaluated alone or with locally administered ipilimumab after surgery. ([nature.com](https://www.nature.com/articles/s41586-024-08507-5))

Other names

Personalized NeoAntigen Cancer Vaccinepersonalized neoantigen peptide vaccine